Skip to main content
BRAIN Biotech AG logo

BRAIN Biotech AG — Investor Relations & Filings

Ticker · BNN ISIN · DE0005203947 LEI · 391200JKPVHLD6JLZ107 F Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2021-05-28 Interim / Quarterly Rep…
Country DE Germany
Listing F BNN

About BRAIN Biotech AG

https://www.brain-biotech.com/

BRAIN Biotech AG is an industrial biotechnology company specializing in the discovery, development, and production of specialty enzymes, high-performance microorganisms, and bioactive compounds. The company provides tailor-made biosolutions and contract research and development (R&D) services to partners in the food, chemical, and life sciences sectors. Core competencies include enzyme technology, microbial strain development, and bioprocess development. By leveraging an advanced technology portfolio, which includes proprietary platforms for enzyme discovery and genome editing, the company enables its partners to create more sustainable and efficient industrial products and processes, contributing to the bioeconomy.

Recent filings

Filing Released Lang Actions
Halbjahresfinanzbericht
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresbericht' (Half-Year Report) for BRAIN Biotech AG covering the period from October 1, 2020, to March 31, 2021. It contains comprehensive financial statements, including the consolidated income statement, balance sheet analysis, and management discussion of financial results. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2021
2021-05-28 German
Report Publication Announcement 2021
Report Publication Announcement Classification · 100% confidence The document is titled "BRAIN Biotech AG: Preliminary announcement of the publication of financial reports..." and explicitly states that it is a 'Preliminary announcement of the disclosure of financial statements'. It details the 'Report Type: Financial report of the group (half-year/Q2)' and provides the 'Date of disclosure: May 28, 2021', which is in the future relative to the announcement date (May 14, 2021). This structure—announcing *when* a report will be published, rather than containing the report itself—fits the definition of a Report Publication Announcement (RPA). The document length is also very short (1798 chars), supporting the 'MENU VS MEAL' rule.
2021-05-14 English
Hinweis auf Halbjahresfinanzbericht vom 01.10.2020 bis zum 31.03.2021
Report Publication Announcement Classification · 100% confidence The document is a short notification (802 characters) informing stakeholders that the 'Halbjahresfinanzbericht' (Interim Financial Report) for the period 01.10.2020 to 31.03.2021 has been published and provides a link to access it. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2021-05-14 German
Hinweis auf Halbjahresfinanzbericht vom 01.10.2020 bis zum 31.03.2021
Report Publication Announcement Classification · 99% confidence The document text is very short (818 characters) and explicitly states that a financial report ('Halbjahresfinanzbericht' - Half-Year Financial Report) is available on the internet, providing a link and the publication date (28.05.2021). It is an announcement about the availability of a report, not the report itself. This aligns perfectly with the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports. The content is not a comprehensive Interim Report (IR) but a notice pointing to it.
2021-05-14 German
BRAIN Biotech AG expands stake in successful enzyme producer Biocatalysts Ltd.
M&A Activity Classification · 99% confidence The document is a press release announcing that BRAIN Biotech AG has expanded its stake in Biocatalysts Ltd. It details the acquisition of additional shares, the financial implications (purchase price, debt release), and future plans regarding capacity expansion. This type of announcement, which concerns corporate transactions, investment strategy changes, and capital structure adjustments (increasing ownership), fits best under the 'Capital/Financing Update' category (CAP) or potentially 'Regulatory Filings' (RNS) as it is a corporate news item disseminated via DGAP. However, since it specifically details an investment/acquisition of shares leading to a change in ownership structure and financing implications (release of provisional debt), 'CAP' is a strong candidate. Given the context of corporate actions involving capital structure and investment, 'CAP' is more specific than the general 'RNS' fallback. It is not an ER, IR, 10-K, or a simple dividend/share repurchase notice, but a strategic investment update. I will classify it as CAP.
2021-05-12 English
BRAIN Biotech AG: Genome Editing Tool Developed by BRAIN
Regulatory Filings Classification · 100% confidence The document is a press release disseminated via DGAP, announcing a scientific development ('Genome Editing Tool Developed by BRAIN') rather than a formal periodic financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or CAP). It discusses R&D progress, potential economic upside, IP filing, and future commercialization models. It is not an Earnings Release (ER) as it doesn't contain financial figures, nor is it a Call Transcript (CT) or Investor Presentation (IP). Since it is a general corporate news announcement about technology and strategy that doesn't fit the highly specific categories like DIRS, MANG, or TAR, the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous news releases distributed through official channels like DGAP.
2021-05-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.